Actuate Therapeutics (ACTU)

Actuate Therapeutics stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · NASDAQ

$0.41▼ -21.59%

Prices as of Oct 26, 2026 · USD

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

40%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Actuate Therapeutics in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Actuate Therapeutics

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Actuate Therapeutics a 40% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.

In half of the simulated outcomes the price ends between $0.28 and $0.49; in 9 out of 10, between $0.17 and $0.79. Estimated annual volatility is 176%.

Price, last 12 months (weekly close)

Key numbers

52-week high: $7.90
52-week low: $0.41
Revenue (12 months): $0.0M
Return on equity: -280.5%
Free cash flow (12 months): $-12.5M
Beta: 0.96

What this means

ATLAS does not publish a fair value for ACTU right now, but it does show its odds of rising: somewhat worse than a coin flip.

Over the last 52 weeks ACTU has traded between $0.41 and $7.90. Today it is 94.8% below that high and 0% above its low.

Its beta is 0.96: it moves roughly in line with the market.

About the company

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers.

Want to see everything about Actuate Therapeutics?

Get started →

Plans from €3.99 a month.

Frequently asked questions

What does Actuate Therapeutics do?

What is the chance ACTU goes up next month?

40%: somewhat worse than a coin flip. In half of the simulated outcomes, ACTU ends the month between $0.28 and $0.49.

How volatile is ACTU?

ATLAS estimates annual volatility at 176%. In a typical month, half of the outcomes end between $0.28 and $0.49.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer